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Abstract
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Although DNA encodes the molecular instructions that underlie control of cell function, it is the
proteins that are primarily responsible for implementing those instructions. Therefore, quantitative
analyses of the proteome would be expected to yield insights into important candidates for the
detection and treatment of disease. We present an iTRAQ (Isobaric Tagging for Relative and
Absolute Quantification)-based proteomic analysis of 10 ovarian cancer cell lines and 2 normal
ovarian surface epithelial cell lines. We profiled the abundance of 2659 cellular proteins, of which
1273 were common to all 12 cell lines. Of the 1273, 75 proteins exhibited elevated expression, and
164 proteins had diminished expression in the cancerous cells compared to the normal cell lines.
The iTRAQ expression profiles allowed us to segregate cell lines based upon sensitivity and
resistance to carboplatin. Importantly, we observed no substantial correlation between protein
abundance and RNA expression or epigenetic, DNA methylation data. Furthermore, we could not
discriminate between sensitivity and resistance to carboplatin on the basis of RNA expression and
DNA methylation data alone. This study illustrates the importance of proteomics-based discovery
for defining the basis for the carboplatin response in ovarian cancer and highlights candidate
proteins, particularly involved in cellular redox regulation, homologous recombination and DNA
damage repair, that otherwise could not have been predicted from whole genome and expression
data sources alone.

NIH-PA Author Manuscript

Keywords
iTRAQ; mRNA expression; DNA methylation; carboplatin; resistance

*

Corresponding Author: Nicholas K. Tonks, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY
11724-2208, Phone: (516) 367-8846; tonks@cshl.edu.
1Current address: New York Genome Center, New York, USA
2Current address: Hospira Inc., Lake forest, IL, USA
4Current address: Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, USA
#These authors contributed equally to the manuscript.
AUTHOR CONTRIBUTIONS
GF, RL and NKT designed the experiments; GF and CF had primary responsibility for performing the experiments; GF, KW, CF, GS,
SP, DP, RL and NKT analyzed and interpreted the data; GF, KW, RL and NKT wrote the manuscript. NKT directed the study.
The authors have no conflicts of interest to report.

Fan et al.

Page 2

INTRODUCTION
NIH-PA Author Manuscript

The American Cancer Society projects there will be approximately 21,980 new cases of
ovarian cancer in the United States in 2014. Of those, an estimated 14,270 will succumb to
the disease. One of the critical steps for treatment of ovarian cancer is identifying those
patients that will respond positively to therapy. A majority of the patients that respond
initially to a primary treatment of surgery and chemotherapy typically suffer recurrence with
a drug-resistant phenotype [1]. Consequently, there is a diagnostic need for both clinical and
molecular features, or biomarkers, that can be associated with early detection, survival and
disease recurrence. Although significant progress has been made in developing technologies
that can simultaneously measure thousands of molecular features in a given patient sample,
statistical methods to analyze this flood of data need to be carefully chosen in order to
identify biomarkers that are more likely to be validated and thus achieve clinical utility [2].
Additionally, experimental and biological limitations in interpreting transcriptional activity
in the context of abundance of cellular proteins have produced few functional genomic and
prognostic commonalties from an abundance of ovarian cancer gene expression studies [3,
4].
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Proteomic analysis, to define the complement and abundance of cellular proteins, facilitates
the identification of pertinent biological processes and the definition of molecular targets
that contribute to a disease state. Presently, proteomic analysis of ovarian cancer is in a
challenging but promising developmental phase that is aimed at identifying successful
strategies for early detection and discovering potential biomarkers of chemosensitivity [5].
In general, proteomic approaches have become an invaluable tool for the discovery of
functional associations with oncogenic signaling pathways and changes in protein
abundance and modification in the disease state [6, 7]. In ovarian cancer, measurements of
cellular protein levels by mass spectrometry have been employed on cell line, tumor and
serum samples to identify candidate biomarkers for disease progression, histological
subtypes and proteins associated with carboplatin resistance [8-12]. Nevertheless, very few
of these studies have been able to quantify protein expression in multiple cancer cell lines or
tissue samples. Furthermore, the critical issue of the extent to which changes in protein
expression coincide with RNA expression or epigenetic variation within ovarian cancer
remains to be defined.
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We have employed the Isobaric Tagging for Relative and Absolute Quantification (iTRAQ)
approach to examine chemosensitivity in cell models of ovarian cancer. The iTRAQ isobaric
chemical labeling technology is often used in discovery MS-based proteomics because it
allows multiple points of comparison, initially four, but more recently eight different
conditions [13]. The iTRAQ reagents are chemical tags that modify the N-terminus (and the
ε-amino group of lysine) of peptides generated by proteolytic digestion of the protein
sample. These tags comprise a reporter group of variable Mr (113-119 and 121 in the 8-plex
system) and a balancer group that ensures the same total mass (305 Da for the 8-plex set) for
each tag. Tryptic peptide samples from various experimental conditions, as many as eight,
are labeled separately with an iTRAQ tag and the samples are then combined. The mixture
is fractionated by ion exchange chromatography or isoelectric focusing to reduce the
complexity of the samples, and each fraction is then subjected to reverse phase nano LC-
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MS/MS. In MS mode, the multiplexed labeling of any given peptide results in an identical
precursor mass; however, following fragmentation in MS/MS mode, each tag releases a
unique reporter ion, the intensities of which are used for relative/absolute peptide
quantitation. An advantage of this approach is that the multiple samples are analyzed
simultaneously. Furthermore, the b- and y-ions derived from the peptides labeled with the
iTRAQ tags remain isobaric, resulting in greater signal intensity in the MS/MS spectra.
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Here, we performed iTRAQ analysis to quantify protein abundance in 10 ovarian cancer cell
lines and 2 normal ovarian surface epithelial cell lines. This was integrated with analysis of
DNA methylation and RNA expression data for each gene product identified by iTRAQ.
There are two major conclusions of the study. First, we observed no significant correlation
between cellular protein content and mRNA expression or methylation data. Therefore, the
extent of mRNA expression was not a direct indicator of the extent of protein expression in
these ovarian cancer cell models. This illustrates that reliance exclusively on global genomic
measurements may miss important features of the disease phenotype. Second, although we
observed no correlation between carboplatin resistance and either RNA expression or DNA
methylation, we did observe a protein signature that directly correlated with carboplatin
resistance. Furthermore, our analysis by iTRAQ revealed a potential role of several redox
regulatory proteins and homologous recombination repair (HRR) pathway components in
carboplatin resistance.

EXPERIMENTAL METHODS
Cell Culture and RNAi
Ovarian carcinoma-derived cell lines were cultured in Dulbecco's Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml) and
streptomycin (100 μg/ml). Normal human ovarian surface epithelium (HOSE) 11-12 and 6-3
control cell lines were grown in 199: MCDB 105 (1:1) medium containing 10% FBS. Cells
were maintained at 37°C in an atmosphere of 5% CO2. Additional information about all of
the ovarian cell lines used in this project is presented in Supplementary Table S1.
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siRNAs targeting catalase and TXNDC5 were purchased from Sigma: catalase siRNA1-3:
SASI_Hs02_00092507, 00092508, 00332471; TXNDC5 siRNA1-3: SASI_Hs02_00171689,
00171690, 00355463. siRNA was delivered into CAOV1 ovarian cancer cells by AMAXA
electroporation (Kit T, Program T-016, Lonza).
iTRAQ (isobaric tag for relative and absolute quantitation) Analysis
Ovarian cancer cells were lysed in a buffer containing 8M urea, 50mM Triethylammonium
bicarbonate (TEAB, pH 8.5) and 0.05% w/v ProteaseMax (Promega) supplemented with
phosphatase and protease inhibitor cocktails (P2850, P5726, P8340, Sigma). Protein
concentrations were determined by the BCA assay (Pierce). A universal standard was
created by pooling 100 μg protein samples from each of the 12 cell lines. This universal
standard (100 μg) was incorporated in each 8-plex iTRAQ experiments to enable robust
quantitation between experiments. Aliquots of 100 μg total protein from each sample were
reduced, alkylated, and then precipitated by a methanol/chloroform precipitation method.
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Protein pellets were reconstituted in 50 μl of 6M urea/50mM TEAB with sonication [14] and
digested by 2% trypsin overnight. iTRAQ reagents (8-plex iTRAQ kit, Sciex) were
reconstituted in ~80 μl of isopropanol and incubated with designated tryptic peptide samples
at 37°C for 2 hrs with mild agitation. Peptides were desalted on a C18 Sep-Pak cartridge
(Waters) and fractionated by high resolution (24-fractions) OFFGEL fractionation [15].
Peptide samples from each fraction were analyzed on a Proxeon Nano LC system coupled to
a LTQ-Orbitrap XL mass spectrometer (Thermo) with an 80 minute gradient at a flow rate
of 300 nl/min. Survey full-scan spectra were acquired with resolution of 15,000 and mass
range from 400-1800 m/z. The top 4 most intense ions were selected for alternated HCD and
CID scans. Protein identification and quantification was carried out with Mascot 2.3 (Matrix
science) against the human IPI database (87,040 sequences). Methylthiolation of cysteine,
N-terminal and lysine 8-plex iTRAQ modifications were set as fixed modifications,
methionine oxidation as a variable modification and one missed cleavage allowance. Peptide
mass tolerance was set at 20 ppm, with 0.6 Da for fragment ions (decoy database false
discovery rate < 2%). iTRAQ ratios were calculated as intensity weighted, using only
peptides with expectation values < 0.05 [15].

NIH-PA Author Manuscript

Analysis of gene expression and detection of methylation in human ovarian cancer cells
We used the Affymetrix Human Genome U133A array: GEO platform identifier GPL96.
RNA was isolated using the trizol protocol, converted into cDNA and the double-stranded
cDNA was used as the template in an in-vitro transcription reaction containing biotinylated
CTP and UTP in addition to the four unmodified ribonucleoside triphosphates. The standard
Affymetrix protocol was applied. Final signal intensities were processed using the RMA
normalization method in the Affy package of R Bioconductor 2.5.
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The protocol for Methylation detection representational Oligonucleotide Microarray
Analysis (MOMA) was performed as previously described [16, 17]. Annotated genomic
CpG island locations were obtained from the UCSC genome browser. At the time of the
experiment the genome contained 26,219 CpG islands in the range of 200–2000 bp. These
CpG island locations were covered by MspI restriction fragmentation. Arrays were
manufactured by Nimblegen Systems Inc. using the 390,000 probes format. The CpG island
annotation from the human genome build 33 (hg17) was used to design a 50-mer tiling
array. The primary restriction endonuclease used was MspI. After the digestion linkers were
ligated and the material cleaned by phenol chloroform, precipitated, centrifuged, and
resuspended. The material was divided in two, half being digested by the endonuclease
McrBc according to specification by New England Biolabs and the other half being mock
digested. Procedures for hybridization and washing were reported previously [16]. The
procedure was performed in duplicate with a dye-swap for the second experiment. The
labels were swapped between the McrBc treated and mock samples. For each probe, the
geometric mean of the ratios (GeoMeanRatio) of McrBc treated and control samples were
then calculated per experiment and its associated dye swap. Microarray images were
scanned on GenePix 4000B scanner and data extracted using Nimblescan software
(Nimblegen Systems Inc). The GeoMeanRatios of all the samples in a data set were then
normalized using a quantile normalization method [18]. All general analysis and statistics
were computed using S-plus, R packages and individual Perl/Python scripts.
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Each cell line (7 epithelial ovarian cancer cell lines and 1 control cell line) was seeded at 103
cells/well in a 96-well plate and treated with carboplatin at a concentration range of 0-100
μg/ml in 100 μl of fully supplemented DMEM. After a period of 72 hrs proliferation was
assessed by MTT (3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide) assay and
absorbance measured at 595nm using the Wallac microplate reader (Perkin Elmer).
Absorbance was converted to the percentage of cells surviving and plotted against the
concentration to calculate the IC50.
CellTiter-Glo Luminescent Cell Viability Assay (Promega) was used to evaluate the role of
Catalase and TXNDC5 in carboplatin resistance. In summary, siRNA was delivered into
CAOV1 ovarian cancer cells by AMAXA electroporation (Kit T, Program T-016, Lonza).
Twenty-four hours later, cells were trypsinized, re-seeded in a 96-well plate at 2 × 103 cells/
well and grown for another 24 hrs. Cells then were treated with carboplatin at a
concentration range of 0-100 μg/ml in 200 μl of fully supplemented DMEM. After 24 and 48
hrs, 20 μl of 1/10 diluted CellTiter-Glo reagent was added to each well, mixed for ~15
minutes on an orbital shaker to induce cell lysis, and followed by luminescence reading.
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Immunoblotting Analysis
Ovarian cancer cell extracts were prepared in RIPA lysis buffer (50 mM Tris HCl pH 8, 150
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing 50 mM sodium
fluoride, 1 mM sodium orthovanadate and 1X complete protease inhibitor cocktail (Roche).
Total protein concentration was determined by the method of Bradford. Proteins were
resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and
transferred to nitrocellulose membrane. Membranes were blocked in 5% BSA in TBST
(20mM Tris-HCl pH 7.6, 136 mM NaCl, 0.1% Tween-20) and incubated at 4°C overnight
with primary antibodies against RPA1, RPA2, MCM2 (kind gifts from Bruce Stillman Lab),
MCM5 (Bethyl Laboratory), catalase (Cell Signaling), TXNDC5 (R&D Systems) and βTubulin (Sigma). Proteins were detected with HRP-conjugated secondary antibodies
(Jackson Lab) and enhanced chemiluminescence (ECL; Pierce).
Bioinformatic Analysis
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All analysis was performed using a combination of Perl/Python scripts and R statistical
functions. We used either iTRAQ raw values or iTRAQ log(2) values where applicable. A
normal distribution of iTRAQ log(2) data per cell line was applied for the determination of
abundance threshold values based on estimated variance. Pearson correlation calculations
and unsupervised cluster analysis was performed via R and the gplots library was
implemented. Pathway enrichment analysis was performed as described previously [19].
Large datasets are provided in Supplementary Tables 2-7.

RESULTS
Quantitative proteomic analysis of control and ovarian cancer cell lines by iTRAQ
We performed an 8-plex iTRAQ analysis to evaluate systematically and quantitatively the
change in protein expression profile between normal ovarian epithelial control cells and
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carcinoma-derived cell lines. To allow comparison between multiple runs, an internal
control was developed, which was composed of an equal mixture of all the samples. The
results of this sample were used to normalize the multiple runs. Protein samples from each
cell line and from the internal control were analyzed on a Proxeon Nano LC system coupled
to a LTQ-Orbitrap XL mass spectrometer. The flow chart of the analysis was illustrated in
Fig 1A. To optimize the experimental conditions and test data reproducibility, a pilot
experiment was performed involving HOSE 6-3, OVCAR-3, PA-1, CAOV-4, CAOV-3 and
A2780 cell lines. Among 881 proteins identified in common between the pilot and final
experiment for these 6 cell lines, we observed consistently high correlation (Fig S1:
Spearman Correlation > 0.71; Pearson correlation > 0.76). In the final study of 12 cell lines,
we identified 87,040 peptides, which represented 3099 proteins. Further protein
identification and quantitation with Mascot identified 2657 proteins, of which 1273 were
found in all 10 ovarian carcinoma-derived cell lines and the 2 control lines that were
examined (Fig 1B and Table S2&3). The number of proteins captured by iTRAQ per cell
line ranged from 1642 to 2289.
Analysis of variability in iTRAQ values among ovarian epithelial cell lines
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We examined the distribution of protein expression among all the cell lines to define the
scope of the changes we observed and to demonstrate the legitimacy of the dataset. In Fig
2A, we present a box plot of the raw iTRAQ values to illustrate the variation between the
internal control and each cell line and the range of iTRAQ measurements. The iTRAQ log(2)
values of 50% of the proteins identified per cell line were between −1 and 1 (within the box,
Fig 2A), and the median varied little among all cell lines. This indicated that there was no
substantial change in ~50% of the proteins detected in each cell line. When this was
extended from 1 to 2 standard deviations away from the mean (within 25-75 percentile, Fig
2A), we captured >98% of the total protein detected. In each cell line, there was a small
number of proteins that displayed a greater magnitude of change; however, these were not
consistent across cell lines.
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We compared the variability in expression of individual proteins between 10 ovarian cancer
cell lines and 2 normal controls (HOSE 6-3 & Hose11-12). We identified 1273 proteins in
common among all the cell lines and determined the “mean-hose-ratio” for each individual
protein, which was the average iTRAQ value from the 10 ovarian cancer cell lines divided
by the average iTRAQ value of the 2 normal control cell lines (Table S4). TUBB (tubulin
beta chain) served as a control in this analysis, with a mean-hose-ratio of 1.01. Among the
1273 proteins, a total of 75 proteins displayed a mean-hose-ratio greater than 1.5, whereas
there were 164 proteins with a mean-hose-ratio less than 0.75. The distribution of the ratios
is summarized in Fig. 2B and all the data are presented in Table S3-4. Furthermore, we
applied the same “mean-hose-ratio” algorithm to mRNA expression and DNA methylation
data for these cell lines (Table S4), and calculated the correlation between iTRAQ and
mRNA expression, or between iTRAQ and DNA methylation. Interestingly, there was no
overall correlation of iTRAQ protein expression with either mRNA expression (Fig 2C) or
DNA methylation (Fig 2D)
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Use of unsupervised clustering of iTRAQ ratios to segregate cells according to sensitivity
to carboplatin.
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We chose 8 out of the 12 ovarian cell lines, 7 cancer and 1 control, for which we had mRNA
expression and DNA methylation data in addition to the results of the iTRAQ analysis.
Using median absolute deviation (MAD) filtering analysis, we calculated the extent to which
expression of a particular protein in a given cell, measured by the iTRAQ score, varied
relative to the median level of expression of that same protein in all of the cell lines tested.
We performed this analysis on Z-scores obtained from the iTRAQ log(2) ratio data for 1279
proteins among each of the 8 cell lines (Table S5). The 300 most variable proteins (Table
S6) were selected for unsupervised hierarchical clustering analysis using a Euclidean
distance complete method. Interestingly, using a heat map to illustrate the expression level
of each protein for each cell line (Fig 3A), we were able to place these proteins into two
classes. Accordingly, we were able to segregate the 8 cell lines into two major clusters,
which, unexpectedly, coincided with the cellular response to carboplatin. Cluster 1
comprised those cell lines with an IC50 in the range 35 - 85 μg/ml, which we categorized as
the “carboplatin-resistant group”. This included cell lines CAOV-1, COLO-316, OVCAR-3,
and OVCAR-5. Cluster 2, the “carboplatin-sensitive group”, comprised cell lines with IC50
lower than 20 μg/ml and contained A2780, PA-1, CAOV-3 and the normal ovarian surface
epithelial cell line Hose 6-3. Consistent with the outcome of this clustering analysis,
candidates associated with DNA damage repair and redox regulation segregated according
to the iTRAQ data as would have been expected between chemoresistant and
chemosensitive cell lines (Table S7).
We also examined data from standard Affymetrix arrays to quantify mRNA expression and
MOMA methylation arrays to assess DNA methylation for the MAD-filtered iTRAQ
proteins. It is important to note that in contrast to data on protein expression, we could not
generate a similar segregation pattern when using either MAD-filtered mRNA expression
data (Fig 3B) or DNA methylation data (Fig 3C) for the same top 300 protein candidates.
Furthermore, when a similar unsupervised clustering analysis was performed solely on
mRNA expression and DNA methylation data for all of the candidate proteins identified in
the iTRAQ experiment in these cell lines, neither data set produced significant clusters nor
did they define chemosensitive cellular subtypes.
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Protein abundance did not correlate with mRNA expression or DNA methylation.
In light of the fact that we were able to classify cell lines as either carboplatin-sensitive or
carboplatin-resistant only on the basis of the protein signature, we examined further whether
there were correlations between protein expression and mRNA expression, as well as protein
expression and DNA methylation. We assigned a positive correlation to decreased DNA
methylation and increased iTRAQ values since decreased promoter methylation corresponds
biologically to an increase in gene expression and therefore presumably increased protein
abundance. The normal distributions for correlation of either iTRAQ-DNA methylation or
iTRAQ-RNA expression show that protein level was poorly correlated with either mRNA
expression or DNA methylation (Fig. 4). A positive correlation of r ≥ 0.5 between mRNA
expression and cellular protein concentration was observed only in 11% of the proteins;
conversely even an anti-correlation r ≤ −0.5 was observed in 7.5% of the proteins sampled.
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These results show that there were roughly equal numbers of genes for which gene
expression correlated with protein level (high gene expression and high protein level or low
gene expression and low protein expression) as there were genes for which expression did
not correlate with protein level (high gene expression and low protein or low gene
expression and high protein level). Similar results were observed for DNA methylation.
Validation of differentially expressed proteins
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The 300 most variable proteins, through which we generated signatures that distinguished
between carboplatin-resistant and -sensitive cell lines, were filtered through the Human
Protein Reference Database (HPRD, Release 9) to illustrate potential protein-protein
interactions. This analysis highlighted 74 of the 300 proteins, with 59 interactions among
them, including 12 single edge (pairs) interactions, 8 multi-protein complex interactions and
two larger protein interaction networks of 6 and 13 edges (Fig 5). Of particular note, we
identified the RPA-MCM complex; correlation between the expression of RPA (replication
protein A), a single-stranded DNA binding protein required for recombination and DNA
repair, and the MCM2 and MCM5 mini-chromosome maintenance complex components has
been reported and implicated as a predictor of survival in serous ovarian carcinomas [20]. In
addition, we performed pathway enrichment analysis for these 300 proteins using the 169
pathways available at the time of analysis in the KEGG database. The most significant of
these were hsa04540-Gap Junction (p=0.0068) and hsa03440-Homologous recombination
(p=0.0146), both of which have been implicated in sensitivity to chemotherapeutic agents,
such as carboplatin. Finally, we searched the Human Protein Atlas to compare the protein
expression levels of the top candidates from our analysis between normal ovary and
malignant ovarian carcinomas. We observed higher expression of S100P, GGCT and CRKL
in human ovarian cancer samples compared to normal ovary, in which these proteins were
undetectable (Fig 6).
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We examined the DNA damage response proteins RPA1, RPA2, MCM2 and MCM5 to
validate further the differential protein expression between carboplatin-sensitive and
carboplatin-resistant ovarian cancer cell lines. Carboplatin-resistant cell lines (CAOV-1,
COLO316 and OVCAR-3) displayed low expression level of all the proteins tested
compared to the carboplatin-sensitive cell lines (A2780, PA-1, CAOV-3 and normal control
HOSE 6-3) (Fig 7A). An exception is OVCAR-5 cell line, which, based on protein
expression analysis, would have been predicted to behave like the sensitive cell lines;
however, it displayed a low carboplatin IC50 (35 μg/μl) compared to the other cells in the
resistant class. We quantified the expression of these proteins in all the cells tested, by
immunoblotting using β-tubulin as an internal normalization control, and as shown in Fig
7B, we observed a similar expression trend to that revealed by iTRAQ analysis.
A mechanism that has been proposed to contribute to carboplatin resistance involves a more
reductive environment in the resistant cell, which can detoxify carboplatin-induced reactive
oxygen species (ROS) production. Consistently, we detected higher expression of three
reductase proteins, namely catalase, TXNDC5 and TXNDC17 in carboplatin-resistant
ovarian cancer cell lines (Table S7). The upregulation of catalase and TXNDC5 in ovarian
cancer cells compared to normal control, especially the most resistant to carboplatin, was

Biochem J. Author manuscript; available in PMC 2016 February 01.

Fan et al.

Page 9

NIH-PA Author Manuscript

confirmed by immunoblotting (Fig 7C). To evaluate further the importance of these genes in
carboplatin resistance, we applied RNAi and selected 3 siRNAs for each gene. As shown in
Fig 7D, 2 of the 3 siRNAs against catalase and all 3 siRNAs against TXNDC5 resulted in
robust knockdown of the targeted proteins. Furthermore, suppression of these genes in the
most resistant CAOV1 cells, with two different siRNAs, consistently increased the
sensitivity to carboplatin (Fig 7E), highlighting their potential importance in carboplatin
resistance.

DISCUSSION
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In order to understand the functional differences between a normal and disease state, it is
important to define the identity and quantity of the cellular proteins, the machines that
implement the function of the cell. In the context of cancer, such insights have the potential
to reveal more precisely the mechanistic determinants of oncogenesis, cancer progression
and therapy response within cancer cells than an analysis of the cancer genome alone. We
have applied iTRAQ, which is one method of quantitative proteomics that can provide
insight into the functional significance of changes encoded in the cancer genome. Here, we
have presented a proteomic profiling of 10 ovarian cancer cell lines and 2 normal surface
epithelial cell lines. As has been observed in other proteomic studies [21, 22], the patterns of
mRNA expression did not correlate with the levels of the cognate proteins. Our analysis
extends this further to demonstrate that DNA methylation, as another representation of gene
regulation, also did not correlate with cellular protein expression.
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Our study already illustrates how proteomic analysis has the potential to contribute insights
into cancer etiology. When we compared the variability in expression levels of individual
proteins between the panel of ovarian cancer cell lines and the normal controls, we observed
that among 1273 proteins in common, 75 were over-expressed >1.5 fold, whereas 164
proteins under-expressed <0.75 fold. The protein that was overexpressed to the greatest
extent was S100P, a member of the S100 family of proteins that contains 2 EF-hand
calcium-binding motifs (Fig 2A). Consistent with our findings, increased levels of S100P
have been reported in multiple tumor cell lines and different tumor types. It has been
proposed that S100P may function in tumor growth and metastasis by Ca2+-dependent
interaction with several critical regulatory proteins [23]. Interestingly, we observed
relatively high protein expression of S100P in our carboplatin-sensitive cell lines, including
PA-1 (iTRAQ: 1.974), A2780 (1.462), HOSE 6-3 (1.159), and relatively low expression in
carboplatin-resistant cell lines, including COLO-316 (0.181), OVCAR-5 (0.225), CAOV-1
(0.797), which is also consistent with a contribution of S100P to chemosensitivity to
carboplatin and paclitaxel in ovarian cancer cells [24]. Additional candidates identified as
overexpressed in the ovarian cancer cells in our analysis include GGCT (gammaglutamycyclotransferase), which has been shown to be a potential biomarker in esophageal
squamous tumors [25] and CRKL (Crk-like protein), a known oncogene [26].
Among those proteins shown to be down-regulated, periostin (POSTN) is a ligand for
integrins that has been reported to induce attachment and spreading, consistent with a role in
cell adhesion [27]. ALDH1A3, a member of the aldehyde dehydrogenase family of
detoxifying enzymes, has previously been linked to breast cancer. A lack of expression of
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ALDH1A3 protein is thought to underlie the impaired production of retinoic acid in several
breast cancer cell lines relative to normal breast tissue [28]. Expression of secernin-1
(SCRN1), first characterized in mast cells with a unique function in exocytosis [29], is a
novel prognostic biomarker of synovial sarcoma, expression of which is associated with
metasis-free survival [30]. We detected expression of secernin-1 in normal control ovarian
cell line HOSE6-3 (iTRAQ: 7.624), whereas we observed consistently lower levels in the
cancer cell lines. Furthermore, we observed that the levels of secernin-1 were lowest in
“carboplatin-resistant” cell lines, including CAOV-1 (1.083) and OVCAR-5 (0.866),
compared with the “carboplatin-sensitive” cell lines including A2780 (2.195) and PA-1
(2.547). Consequently, our data suggest that secernin-1 may have potential as a prognostic
biomarker in ovarian cancer. Of note, we reported previously that the protein tyrosine
phosphatase PTP1B, encoded by the PTPN1 gene, served to inhibit IGF-1R signaling that
was essential for ovarian cancer cell proliferation, migration, invasion and anchorage
independent growth [31]. In fact, we observed down-regulation of PTP1B (mean-hose-ratio:
0.82) among all the ovarian carcinoma-derived cell lines tested, compared with HOSE 11-12
& 6-3, consistent with enhanced IGF-1R signaling in the cancer cells.
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Using an ICAT-based quantitative proteomic technique, Stewart and co-workers published
an analysis of proteins associated with cisplatin resistance in ovarian cancer cells [21].
Compared to their work, our studies have extended the scope of the cell lines analyzed and
increased the number of proteins captured in our iTRAQ-based quantitative analysis.
However, perhaps the most striking results of our analysis were the observation that
quantitative proteomics can be used to distinguish cells on the basis of their sensitivity to
carboplatin treatment and the fact that such a “protein signature” could not be discerned
from analysis of either DNA methylation of mRNA expression. This reinforces our position
that quantitative analyses of the proteome have the potential to provide crucial insights that
will help us to understand the molecular mechanism of chemoresistance.
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The active form of cis-platin is a “bi-aquated” species, in which chloro groups are
substituted with water molecules. These activated cis-platin derivatives bind DNA and
generate inter-strand crosslinks, which trigger the cytotoxic response. In addition, the
hydrated cis-platin interacts with endogenous nucleophiles, including cysteines in such
molecules as reduced glutathione, GSH. This has the potential to trigger an oxidative stress
condition, which also favors DNA damage [32]. Interestingly, it has been reported that cisplatin resistance correlates with elevated protein expression of GSH, together with the
enzyme that catalyzes GSH synthesis, γ-glutamylcysteine synthetase, and the enzyme that
mediates the conjugation of carboplatin and GSH, glutathione S-transferase in patientderived cells [33]. In our studies, we also observed high protein expression levels of
glutathione S-transferase (especially glutathione S-transferase omega 1, GSTO1) and
glutathione reductase in ovarian cancer cell lines that are resistant to carboplatin (Table S6).
Furthermore, we observed that proteins related to thioredoxin, namely thioredoxin domain
containing 5 & 17, also displayed elevated expression in carboplatin-resistance ovarian
cancer cell lines (Table S7 and Fig 7C). A similar pattern was observed for catalase (Table
S7 and Fig 7C). Importantly, we demonstrated that our panel of carboplatin-resistant cells
could be sensitized to the effects of the chemotherapeutic agent by RNAi-induced
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downregulation of either TXNDC5 or catalase (Fig 7D-E), suggesting that an enhanced antioxidant environment within the cell may contribute to chemotherapy resistance. The use of
cytotoxic gold compounds, which display similar structural features to platinum (II)
complexes, has been proposed as one approach to overcoming resistance to platinum-based
therapies. It is interesting to note that proteomic profiling of the effects of such gold
compounds on A2780 ovarian cancer cells also revealed changes in proteins involved in
control of redox homeostasis, for example, thioredoxin-like protein 1 [34] and GSH and
thioredoxin reductase 1 (TXNRD1) [35].
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Our quantitative analysis also revealed the potential importance of DNA damage repair
proteins, including elevated levels of single strand DNA-binding proteins RPA1-3 and
MCM2/MCM5 in carboplatin-sensitive cells. Furthermore, RPA plays an essential role in
the recruitment, binding and stabilization of BRCA2/RAD51 in DNA damage response [36].
Perhaps an increase in RPA concentration may compete with RAD51 for single strand DNA
localization and BRCA2 interaction thereby stalling DNA repair and making the cells
sensitive to carboplatin? In addition, our iTRAQ data also highlight other signaling
components/pathways that may be crucial to carboplatin resistance. Jab1/CSN5, which is a
highly conserved protein complex that is implicated in cell cycle control, apoptosis as well
as the DNA damage response and DNA repair, is overexpressed in various cancers including
nasopharyngeal carcinoma, where it coincides with poor prognosis. It has been reported that
suppression of Jab1/CSN5 induced chemosensitivity in nasopharyngeal carcinoma [37],
consistent with our observation that it was elevated in the carboplatin-resistant ovarian
cancer cell lines. In addition, we observed that the levels of intergrin-linked kinase (ILK)
were also increased in the carboplatin-resistant cancer ovarian cells, consistent with reports
that KP-392, a small molecule inhibitor of ILK, exerts a beneficial therapeutic effect in
combination with cisplatin in lung cancer [38]. Galectin-1/LGALS1, another protein whose
function is involved in cell-cell and cell-matrix interactions, was also elevated in resistant
cell groups. Interestingly, aberrant expression of Galectin-1 could promote lung cancer
progression and chemoresistance (to cisplatin) by upreguating p38MAPK, ERK and
cyclooxygenase-2 [39]. We also detected high expression of calcium-dependent
phospholipid binding protein annexin A4 in resistant cells, down-regulation of which by
RNAi could sensitize mesothelioma cells to cisplatin [40]. In contrast, we demonstrated that
expression of phospholipase A2-activating protein (PLAA), RNA-binding protein RBM3
and Bid, which have been reported to enhance cisplatin-induced apoptosis [41, 42], were
lower in the resistant compared to sensitive ovarian cancer cells in our study.
In summary, although current high-throughput genomic strategies focus on the discovery of
gene mutations and altered transcription to help identify novel drug targets, here we
demonstrate the importance of proteomic analysis to reveal changes in the level of
expression of proteins that are critical for therapy response and treatment outcome, changes
that would not be revealed by analysis of mRNA expression or methylation data alone. Our
study to date highlights the potential significance of proteins that regulate cellular redox
status and DNA damage repair, suggesting additional approaches to enhance
chemotherapeutic strategies for treatment of patients with ovarian cancer. Overall, our
results reinforce the importance of developing further appropriate technologies for
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quantitative analyses of the proteome to reveal novel candidates for the detection and
treatment of disease.
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Figure 1. Quantitative proteomic analysis of ovarian control and cancer cell lines

(A) Experimental strategy for iTRAQ-based quantitative proteomics analysis. (B)
Identification of shared ovarian proteome and distinct proteins from each cell line.
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Figure 2. Variability analysis of iTRAQ values among ovarian cell lines

(A) A box plot of the raw iTRAQ values to illustrate the variation between cell lines and the
range of iTRAQ measurements. The distribution range of iTRAQ measurement per protein
identified is presented for 10 ovarian cancer cell lines and 2 normal ovarian surface
epithelial cell lines. The log2 value of each iTRAQ measurement was used to determine
protein abundance per cell line. (B) Variability comparison in expression levels of individual
protein between 10 ovarian cancer cell lines and 2 normal control cell lines. Waterfall plot
was employed to summarize the “mean-hose-ratio” for each of the 1273 common proteins.
(C) Correlations of iTRAQ “mean-hose-ratio” with mRNA expression. (D) Correlations of
iTRAQ “mean-hose-ratio” with DNA methylation.
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Figure 3. Hierarchical clustering of iTraq z-scores for ovarian cancer cell lines
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(A) The top 300 most variable iTRAQ proteins determined by median absolute deviation
were clustered using the Eculidean complete method for the indicated ovarian cancer cell
lines. Minimum z-scores are depicted in red and maximum z-scores are in green. Each row
represents an individual protein, each column is the sum of the proteins identified in the
indicated cell line. Carboplatin survival curves were determined by performing MTT cell
viability assay and plotted for the 7 epithelial ovarian cancer cell lines and one control cell
line. Absorbance was converted to the percentage of cells surviving and plotted against the
concentration to calculate the IC50. Carboplatin-resistant cell lines were labeled “R” and
cell lines sensitive to carboplatin treatment were labeled “S”. (B) Unsupervised hierarchical
clustering of the same 300 most variable iTRAQ proteins using mRNA expression data. (C)
Unsupervised hierarchical clustering of the same 300 most variable iTRAQ proteins using
DNA methylation data.
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Figure 4. Correlation of iTRAQ Data with RNA Expression and DNA Methylation

The correlation distribution of RNA expression (dashed line) and DNA methylation (solid
line) with iTraq data is shown at r = 0.2 binned increments. Note: a positive correlation for
DNA methylation and iTraq values signifies hypomethylation with increased iTraq protein
value.
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Figure 5. Proteomics-derived ovarian cancer modules

Protein-protein interactions of the 300 MAD filtered iTRAQ proteins examined through the
HPRD (Release 9) data base.
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Figure 6. Expression of S100P, GGCT and CRKL in normal ovary and ovarian carcinoma tissue
samples

(A) “Mean-hose-ratio” of S100P, GGCT and CRKL from iTRAQ. (B) Representative tissue
microarray cores showing high expression of S100P, GGCT and CRKL in malignant
ovarian carcinoma sections compared to normal ovary. Data were adapted from The Human
Protein Atlas. (C) Summary of the immunohistochemistry result for all three proteins.
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Figure 7. Biochemical validation of the role of iTRAQ candidate proteins in carboplatin
chemosensitivity

(A) Cells were lysed in SDS-containing RIPA buffer and protein expression levels were
measured by immunoblotting with the indicated antibodies against RPA1, RPA2, MCM2,
MCM5 and β-Tubulin, used as a normalization control. Results have been verified in
duplicate (n=2). (B) Results from (A) were quantitated with program ImageJ and the relative
ratio after normalization was compared in parallel with iTRAQ value per gene per cell line.
(C) Analysis of the expression of catalase and TXNDC5 by immunoblotting with indicated
antibodies. Results have been verified in triplicate (n=3). (D) Control and target gene siRNA
were electroporated into CAOV1 cells. After 48hrs, knockdown efficiency was
demonstrated by immunoblotting. (E) 24hrs after siRNA delivery, CAOV1 cells were reseeded into 96-well plates. Carboplatin was then added and incubated for indicated time.
CellTiter-Glo Luminescent Cell Viability Assay was performed to illustrate the carboplatin
response. Results represent mean ± S.D. from three independent experiments.
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